Digital solutions are increasingly pushing to the forefront of the healthcare discussion. Driven by patients’ interest for improved access to healthcare, several innovative players in the space have generated appealing clinical data on the benefits of digital. Healthcare systems have seen the potential digital has to improve the status quo for all stakeholders involved and have adapted accordingly, with new policies to improve their use of digital solutions.
Having explored this topic with companies at the forefront of digital therapeutics (DTx) development – in a recent study conducted with the Digital Therapeutics Alliance (DTA) – Ipsos has gathered and digested the manufacturer’s perspective on payer discussions and negotiations.
Join us for a complimentary webinar to hear Ipsos and DTA experts share a review of manufacturer experiences with payer assessments of DTx for pricing and reimbursement purposes, in both the U.S. and EU3 (France, Germany & UK). Attend our session and take a journey into the manufacturer mindset on the requirements, opportunities and challenges for DTx.
- A summary of DTx payer drivers
- Key learnings on DTx pricing & reimbursement pathways
- An understanding the challenges and opportunities of DTx pricing & reimbursement
If you can’t attend live, please register to receive the recording!
Davide Panciera, Senior Consultant, Market Access, Ipsos
Megan Coder, Executive Director, Digital Therapeutics Alliance
[WEBINAR] Sharpening Physician Insights by Integrating Patient Record Auditing
The global healthcare landscape is rapidly changing; in order to successfully compete, companies must stay up to date on the latest treatment paradigms. Traditional market intelligence platforms often generalize how patient factors shape the treatment landscape, leaving companies wondering how they can deliver further value to physicians. Drawing from unique patient experiences, record auditing can identify how specific patient factors influence physicians’ decisions, delivering insights you need to identify treatment gaps and develop targeted solutions.